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Abstract 
Despite improvements in modern cardiovascular therapy, the morbidity and mortality of 
ischemic heart disease (IHD) and heart failure (HF) remain significant in Europe and 
worldwide. Patients with IHD may benefit from therapies that would accelerate natural 
processes of postnatal collateral vessel formation and/or muscle regeneration. Here, we 
discuss the use of cells in the context of heart repair, and the most relevant results and 
current limitations from clinical trials using cell-based therapies to treat IHD and HF. We 
identify and discuss promising potential new therapeutic strategies that include ex vivo  
cell-mediated gene therapy, the use of biomaterials, and cell-free therapies, aimed at 
increasing the success rates of therapy for IHD and HF. The overall aim of this ESC 
Working Group Cellular Biology of the Heart Position Paper is to provide recommendations 
on how to improve the therapeutic application of cell-based therapies for cardiac 
regeneration and repair. 
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1. Stem cells in the context of heart repair  
Stem cells are defined as cells with the ability (i) to self renew  by dividing to make copies 
of themselves and (ii) to differentiate to at least one other cell type (1). In the context of cell 
transplantation and heart repair, the term "stem cells" has been widely used but in 
retrospect, some of the cells used do not match the definition of a stem cell. Cells with 
various molecular and functional properties have been isolated from the heart and termed 
"cardiac stem cells" (CSCs), "cardiac progenitor cells" (CPCs) or "cardiomyocyte 
progenitor cells" (CMPCs) (2, 3). These cells can self renew in culture, and differentiate 
into different lineages (endothelial cells and mesenchymal cells) but for example have 
limited cardiogenic differentiation capacities except under exceptional circumstances. By 
the addition of compounds that induce demethylation, human CMPCs do form 
cardiomyocytes (3a). Otherwise the only "stem cells" that form cardiomyocytes using 
mixtures of growth factors, that have been collectively referred to as "cardiogenic 
cocktails", are pluripotent stem cells (PSCs). PSCs can be of embryonic origin (embryonic 
stem cells, ESCs) or created by re-introducing cell cycle genes into terminally 
differentiated cells, to make what are called induced pluripotent stem cells (iPSCs) (1). 
Another term now generally? regarded as incorrectly used is "endothelial progenitor cells" 
(EPCs). These cells were originally isolated as populations that grew in culture from 
peripheral blood samples (reviewed in (4)). They could form networks that resembled 
vasculature, but they turned out not to be true endothelial cells. Finally, cells that adhere 
onto tissue culture plastic in serum-containing growth medium and have adipogenic, 
osteogenic and chondrogenic differentiation potential in culture were termed mesenchymal 
stem cells (MSCs) (5). However, these cells have not been isolated clonally as single cells 
and could therefore be heterogeneous cell populations. Moreover, with the exception of 
those derived from bone marrow, these effects are not observed in vivo. Thus despite 
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them all expressing a similar set of surface markers, these cells are now called "bone 
marrow derived mesenchymal stromal cells" (BM-MSCs) or adipose tissue-derived 
mesenchymal stromal cells (AT-MSCs) (6). These MSCs  have not been shown to 
spontaneously differentiate  into cardiomyocytes.  
For the purposes of this position paper, we use the terminology as in the (historic) 
literature for the sake of clarity but are aware of the caveats in the terminology itself. 
 
2. Translation of cell therapy: successful preclinical stories with uncertain 
clinical  efficacy  
Ischemic heart disease (IHD) and heart failure (HF) remain major causes of morbidity and 
mortality worldwide (7, 8). Potentially valid clinical strategies aimed at repairing damaged 
heart muscle and ischemic tissue, and increasing the heart’s regenerative potential, are 
currently being developed in clinical trials (2, 9). Despite originally high expectations fueled 
by exciting scientific progress, and although long-term, randomized clinical trials have 
shown reassuring safety profiles for intracoronary delivery of cells (2, 11-16), regenerative 
therapy for cardiovascular disease has had inconsistent and modest efficacy thus far (9, 
17-23). Several limitations of most previous clinical trials of cell-based therapies were 
raised and should be addressed before we can fully understand the potential of these 
approaches (see Table 1).  
As a consequence, several strategies have been developed to further improve cardiac 
function in response to cell delivery. The different strategies and protocols, collectively 
referred to as ‘cell enhancement’, are discussed in the section "Critical issues on protocols 
for cell-based therapy".  
In this ESC WG Cellular Biology of the Heart Position Paper, we critically review the 
current approaches using stem cell or cell-based therapies to treat IHD and HF, and 
discuss promising new strategies for stem cell therapy enhancement, with the aim of 
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increasing the efficacy and outcome of stem cell therapies in the future. The overall 
objective of this ESC Working Group Cellular Biology of the Heart Position Paper is to 
provide recommendations on how to improve cell-based therapies for cardiac regeneration 
and repair in IHD and related HF. 
 
2.1 Cell sources used in clinical trials 
Several types of cells have been used in clinical trials, most of them derived from bone 
marrow (12, 14, 15, 17-22, 24-29), or peripheral blood (30, 31), although some studies 
have used mesenchymal stromal cells (MSCs), cultured from a variety of tissue sources 
(Table 2). These heterogeneous cell populations used in the early years of regenerative 
cardiac medicine, have been called “first-generation” stem cells, in contrast with 
contemporary “second-generation” counterparts. The latter consist of more purified cell 
populations with a presumed greater potential for cardiac repair and are often derived from 
non-bone marrow sources, or subjected to genetic and pharmacological “priming” in vitro 
to enhance their engraftment, survival, plasticity and paracrine activity. MSCs exhibit low 
immunogenicity, making allogeneic application feasible. Since the quality and number of 
cells may diminish in patients who are older or have comorbidities or genetic defects 
(reviewed in (32)), allogeneic MSCs can be used from young healthy individuals. Five 
systematic reviews and meta-analyses have reported a significant improvement in left 
ventricle ejection fraction (LVEF) of 2-4% and a reduction in infarct scar size and left 
ventricular end-systolic volume after intramyocardial transplantation of bone marrow cells, 
but all are regarded as surrogate endpoints and not clinically relevant endpoints (or: 
surrogate endpoints with uncertain clinical relevance) (23, 33-36). This is in contrast with 
the outcomes of studies based on small cohorts of patients. Among various possibilities 
(discussed in Table 1), these modest results and the variability between trials have been 
attributed to the different isolation protocols used, which may profoundly impact the 
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function and number of bone marrow cells or blood-derived EPCs actually delivered to the 
patient (37, 38). Therefore, the general consensus is that assessing cell number and 
viability along with careful cell characterization and functionality is necessary before 
delivering cells into patients in any clinical trials. Moreover, the effect of bone marrow 
mononuclear cells on incidence of death, recurrent myocardial infarction or stroke and 
hospitalization for heart failure remains to be determined in adequately powered 
prospective clinical trials.  
Cardiac-derived progenitor or stem cells (CPCs / CSCs) have very recently entered 
the clinical trial arena. Although isolation of these cells from the heart is more invasive than 
bone marrow, long culture periods are required to obtain sufficient numbers for 
transplantation, and their number and functional activity may decline with age, their 
intrinsic paracrine activity (39-41) is expected to make them potentially good candidates 
for enhancing myocardial function in HF patients. Except for the small scale 
transendocardial mesenchymal stem cells and mononuclear bone marrow cells for 
ischemic cardiomyopathy (TAC-HF) trial, comparative clinical data between bone marrow-
derived cells (BMCs), MSCs and CPCs/CSCs is not available in HF.  A few comparisons 
have been done in animal models of myocardial infarction (reviewed in (42)), and MSCs 
seemed to transfer more benefit on systolic function than BMCs in a chronic large animal 
model of myocardial infarction (43). Preclinical research thus far suggests the greatest 
potential functional benefit for CPCs/CSCs from the heart, followed by MSCs, with BMCs 
having more modest effects on LVEF (44). Conclusions about the effect on mortality of 
BMC therapy after acute myocardial infarction (AMI) are expected to derive from the 
ongoing phase III BAMI trial, despite the lack of an appropriate? placebo control injected 
group (https://clinicaltrials.gov/ct2/show/NCT01569178). Likewise, conclusions on the use 
of MSCs alone or in combination with c-Kit positive CSCs will be drawn from the NHLBI 
CCTRN “Concert Trial”, which will probably be initiated before the end of 2015. 
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Of note, there is still no consensus on whether transplanted cell numbers or survival in 
vivo are crucial for effect size. While trial-based meta-analysis suggested a relationship 
between cell numbers and effect in clinical trials, individual patient-based meta-analysis 
have not confirmed this relationship (45).  
 
2.2 Pluripotent stem cells in clinical trials 
Another class among the second-generation cells are pluripotent stem cells, both 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) (Table 2). A 
clinical trial with ESC-derived cardiomyocytes in severe HF (ESCORT) has been initiated 
in France and is being monitored with both interest and caution (46, 47). Since the same 
differentiation protocols for ESCs are effective in iPSCs, it may be expected that this will 
also move forward for the treatment of the heart. iPSC-derived cardiomyocytes have not 
yet been tested in humans, despite the possibility of them being autologous, largely 
because of the extra risk of genetic mutation inherent to the reprogramming method as 
such. Congruently, the first results of ESC-mediated eye repair are encouraging (48) and 
iPSCs for this aim are in clinical trial since September 2014, but the latter study is on hold 
since July 2015 for the identification of a mutation in an oncogene in one of the human 
iPSC lines (http://www.ipscell.com/2015/07/firstipscstop/). This next-generation iPSC-
derived approach is therefore still fraught with uncertainty in the absence of a regulatory 
framework or guidance about “allowable” levels of mutations and methods of their 
detection in iPSC products. 
  
2.3 Cell-free approaches  
A general consensus is that first generation cells may exert any effects on tissue repair by 
secretion of paracrine factors. These largely unknown factors may stimulate the 
myocardium via myocyte salvage, induction of angiogenesis or stimulation of myocyte 
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division. Although the second generation cells, e.g. CPCs/CSCs and iPSC-derived 
cardiomyocytes, have been suggested (CSCs) or proven (pluripotent cells) to have greater 
regenerative capacity because of their ability to form new myocardium, the contribution of 
remuscularization vs. “paracrine effects” to overall efficacy has not been demonstrated 
clinically nor preclinically. Any effects they have are thought to be also mediated via 
paracrine mechanisms. Since functional improvement is not necessarily related to cell 
survival (49, 50), approaches have been developed to mimic the benefit of cell therapy 
without transplanting the cells. Such strategies include stimulating endogenous repair, e.g. 
by promoting neovascularization or activating resident progenitor cells (51, 52). Mediators 
of paracrine effects are thought to include growth factors (e.g. erythropoietin, G-CSF) (53, 
54), episomes (55) and non-coding RNAs (56), mimicking the secretome of donor cells. 
These factors can also be combined by assembling them in different controlled release 
formulations, such as microbeads (57), large scaffolds, or injectable biomaterials (58). 
Recent developments for cell-free approaches that emanate from cells such as these, 
presently focus on secreted nanosized vesicles, called extracellular vesicles, and include 
microvesicles and exosomes (59, 60). These small lipid containing vesicles are capable of 
transferring proteins, mRNA, and miRNAs between cells, and therefore represent a way 
for intercellular communication and inducing cardiac repair (61). However, organ selectivity 
after systemic delivery or inadvertent systemic spread after intracoronary or 
intramyocardial delivery of these nanoparticles remains unknown and a topic for further 
scrutiny. 
 
In summary, although the superiority in cardiac repair of one type of cell compared 
to another has not yet been proven, since very few preclinical studies compared 
them head-to-head, BMCs continue to be the source of cells most often used in 
9 
 
human clinical trials. In cardiac patients, direct comparative data between different 
cell types is notoriously lacking since adequately powered, randomized clinical 
trials with head-to-head comparisons of different cell types have not yet been 
performed. However, at least one study is planned to begin before the end of 2015. It 
is a NHLBI CCTRN trial with cardiac c-Kit cells alone and combined with other cell 
types versus placebo in patients with ischemic cardiomyopathy. Apart from the risk 
of immune rejection, which can potentially be solved using MSCs, allogeneic 
somatic/adult cells appear to be safe. To match reported levels of functional cardiac 
improvement, cell therapy without the cells via paracrine factors may be an 
interesting alternative. For functional improvement beyond current levels achieved 
via paracrine actions, new developments will be necessary for proper regeneration 
of lost tissue. 
 
3. Critical issues on protocols for cell-based therapy 
One major problem for cell therapy is the relatively poor levels of cell retention in the 
transplanted area, and this may not be limited to first generation cells but apply to all cell 
sources. In fact only ≤ 10 percent of injected cells remained at the targeted location. No 
cells survive when injected into the infarct scar, short-term engraftment is ~ 8% regardless 
of injected cell dose in remote normal myocardium, and in the infarct border zone the 
percent survival at 24 h decreases progressively from ~ 8% to  1% (62, 63).  
 
3.1 Improving cell coupling, differentiation, survival and retention by cell 
modification, conjugation with biomaterials or tissue engineering and 
cytoprotection pathways 
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To improve cell retention, several biomaterial-based approaches have been explored 
(e.g. hydrogels, cell sheets, prefabricated matrices, microspheres and injectable 
nanomatrix) (58, 64, 65). An alternative approach, explored in animal models, is the 
implantation of engineered heart tissue made in vitro from cardiomyocytes and hydrogel 
(66). Another method is the use of bispecific antibodies that bind to the cells and 
recognize a cardiac-specific antigen that is only present in injured myocardium (67). 
Localized hypoxia, inflammation, excessive oxidative stress, lack of supporting cells, 
poor supply of nutrients, and fibrosis promote apoptosis or necrosis of the grafted cells. 
Thus, the efficiency of cell therapies might be improved by using genetic engineering 
tools including overexpression of pro-survival genes (e.g. Akt, Pim-1 kinase, ERK1/2, 
HIF-1α, heme-oxygenase 1, GATA4, heat shock protein 27, miRNA-1, myocardin, and 
protein kinase G1α) or angiogenesis-initiating genes (e.g. VEGF, MYDGF, FGF-2, SDF-
1, PDGF) in the cells to be transplanted or by transplanting the cells together with pro-
survival or pro-angiogenic factors (42, 63, 68-74). Interestingly, exposure of cells to sub-
lethal hypoxia increased the tolerance of these cells to the harsh environment after 
transplantation (75). These preconditioned cells showed also increased differentiation, 
enhanced paracrine effects leading to increased trophic support, and improved homing 
to the lesion site (75). Transplantation of preconditioned cells helped to suppress 
inflammatory factors and immune responses, and promoted heart function (75). In 
addition, transient modulation of cell specification towards myogenic differentiation e.g. 
via microRNAs, could also be beneficial in increasing the amount of myocardium. For 
this, miR-1 and 499 are excellent candidates as they can enhance both differentiation in 
vitro (76) and in vivo (77). Another approach to promote transplanted cell survival is to 
modulate the inflammatory environment (using TSG-6, IL-1 inhibitor) (70, 78). Finally, a 
significant barrier to the therapeutic use of most cell populations with the exception of 
ESCs and iPSCs, is their limited cardiac differentiation potential despite the use of 
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“cardiogenic cocktails” (containing TGF-β1, BMP-4, activin A, retinoic acid, IGF-1, FGF-
2, α-thrombin, and IL-6) and overexpression of cardiac transcription factors (79-81). In 
addition, these stem cells fail to electromechanically integrate (82). This limitation has 
been partially solved by overexpressing the two key proteins, N-cadherin and connexin 
43, but clinical translation remains to be fully investigated. By contrast, human iPSCs can 
now be routinely differentiated with high efficiency (>80%) into cardiomyocytes (83). 
However, the cardiomyocyte populations may contain varying proportions of atrial, 
ventricular and nodal cardiomyocytes (84, 85). This is a critical issue as they have 
unique mechanical and electrical properties and thus the implantation of a mixture of 
these cells harbors the risk of arrhythmias (86). In addition, all of these cardiomyocyte 
types are immature and beat spontaneously, another source or arrhythmogenic risk. 
Consequently, even though many protocols primarily give rise to ventricular like 
cardiomyocytes, it is important to refine the differentiation protocols to produce pure 
populations of defined cardiomyocyte phenotype (87, 88). In addition, a robust cardiac 
lineage differentiation state of all transplanted cells is critically important to avoid the 
formation of teratomas.  
 
3.2 Stem cell rejuvenation 
Aging or comorbidities may cause a reduction in the number and function of tissue-
resident and circulating cells (32, 89, 90). Several proteins and signalling pathways have 
been identified that are capable of reverting the process of cell senescence, including Pim-
1 kinase (91-94), NOTCH1 (95-97), telomerase and myocardin (98). Pim-1 kinase has 
anti-senescence and anti-apoptotic effects in CSCs as well as in MSCs (92). Activation of 
the NOTCH1 signaling pathway results in remarkable rejuvenation of satellite muscle cells 
associated with enhanced proliferation, increased telomere lengths, and decreased 
susceptibility to replicative senescence (95). The overexpression of telomerase and 
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myocardin genes increases cell survival, proliferation, cardiomyogenic (99, 100), and 
smooth muscle differentiation in vitro (101). After overexpression of genes encoding for 
“rejuvenating factors’ and in vitro expansion, genetically modified cells may secrete high 
amounts of the regenerating factor, either transiently or permanently, at the site where 
they have been transplanted (68, 102). Taken together, the design of new protocols for 
aged cell rejuvenation would allow improved cell preparation and clinical application of 
cells in aged patient populations. 
 
3.3 Enhancing endogenous cardiac regeneration 
Recent studies have demonstrated that cardiomyocyte turnover occurs throughout life in 
mammals, including humans (103-107). While the estimated rate of human cardiomyocyte 
renewal is controversial, most labs find an annual turnover rate of 1%, which increases 
after injury. However, the intrinsic capability in humans to regenerate injured myocardium 
after massive ischemic cell death is too low to be of functional relevance. It has been 
suggested that transplanted cells may exert their beneficial effects by secreting cytokines 
and growth factors promoting cardiomyocyte proliferation, recruitment and activation of 
CPCs, induction of vessel formation, reduction of fibrotic scars, and inhibition of apoptosis 
(108). In addition, modulation of macrophage and regulatory T-cell function can improve 
healing, repair and regeneration (109; 109a). Another approach to enhance endogenous 
cardiac repair is the induction of cardiomyocyte proliferation, a mechanism described in 
neonatal mice, zebrafish and newts in response to injury (110) although never in adult 
mammals. However, blocking the Hippo pathway or upregulating the downstream Hippo 
effector Yes-associated protein (Yap), may promote cardiomyocyte regeneration after 
myocardial infarction (10). Alternatively, application of the human Fstl1 protein (FSTL1) via 
an epicardial patch stimulates cell cycle entry and division of pre-existing cardiomyocytes 
(110a). 
13 
 
   
3.4 Cell tracking and injection systems  
In vivo cell tracking involves either 'direct' physical labelling of cells by incubating them 
with a contrast agent, or 'indirect' genetic labelling by transfecting cells with a reporter 
gene construct. The position of, and signal from these labels can then be tracked using 
various imaging modalities including clinical scanners, such as positron emission 
tomography (PET), single photon emission computed tomography (SPECT) and magnetic 
resonance imaging (MRI) (reviewed in (111, 112). Given its high anatomical resolution and 
safety profile allowing serial longitudinal evaluations, MRI has been commonly used to 
track cells in clinical trials (113). However, MRI might detect macrophages that ingest the 
marker after the cell (derivative) dies. Safety concerns regarding the effects of genetic 
manipulation of cells currently limit the use of genetically modified cells in clinical trials, 
and thus long-term cell tracking. However, combination approaches relying on the 
simultaneous co-registration of different imaging modalities (nuclear medicine combined 
with CT or MRI) might overcome the limitations of individual imaging techniques, and 
represent powerful tools to gain insight into the delivery, engraftment, survival, off-target 
and possible adverse effects of transplanted stem and progenitor cells. Given the 
indispensable role of cell tracking in clinical trials, the feasibility of imaging should be 
included in preliminary proof of concept studies, and considered among inclusion or 
exclusion criteria, but will limit cell transfer studies to only a few centers that have access 
to multimodal imaging expertise.  
 
3.5 Controls, data reproducibility, standardization issue and data quality 
Over the past few years, concerns have been increasingly voiced about experimental 
reproducibility across the whole biomedical research fields (114, 115), especially cell 
therapy. For example, a recent paper searching for errors in published cardiac clinical 
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trials using autologous BMCs reported that the greatest enhancement of LVEF was 
described in those studies with the most discrepancies or errors in factual reporting (116). 
The pervasive risk of neglecting basic rules of clinical trial design in stem cell trials has 
been demonstrated in a recent review (117). On the other hand, phase II studies, where 
the aim is to prove efficacy should be designed to assess several primary end-points, 
which might include structural evaluations, cardiovascular physiological measurements, 
biomarkers, functional capacity, and quality of life (118).  
The choice of appropriate controls and methodological rigor may be more demanding in 
the field of cell therapy if, for example, the need for a myocardial biopsy to harvest 
autologous stem cells complicates double-blinding. A pragmatic alternative is to use a 
crossover study design, in which each patient is randomly assigned to a sequence of 
treatments. However, where reagents such as cytokines are administered in conjunction 
with cells, a control group with cytokines alone should also be included. Another issue is 
the choice of the right placebo control, which, in some cell therapy trials, simply consisted 
of transparent saline solution which easy to distinguish visually from serum. 
Standardization of cell isolation and processing procedures is highly desirable in order to 
facilitate comparisons between trials and to enable meta-analyses. Standardization of 
patient populations and stratifications should also be attempted. It has been proposed that 
reference MSCs be developed to facilitate comparison between studies (119). 
 
In summary, cell-based therapies would benefit significantly from different 
protocols collectively referred to as cell enhancement, including possible priming of 
host tissue with cytokines to increase homing; preconditioning of transplanted 
cells, drugs and pro-survival factors; genetic engineering of cells; and the use of 
biomaterials. All of these strategies could contribute to improving cell retention and 
promote cell survival, proliferation, differentiation and induction of neo-
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angiogenesis. Nevertheless, irrespective of cell enhancement, pilot studies to 
understand where the cells go by choosing the best tracking system in vivo, and 
adherence to well-established rules for the design of robust clinical trials, are 
minimum requirements for any cell protocol to assess actual effectiveness of cell-
based clinical interventions. 
 
4. Clinical trial design 
4.1 Safety and ethical issues 
The design of randomized controlled clinical trials that are able to ascertain the long-term 
safety of cell therapy, can be challenging from an ethical perspective, and encompass 
issues related to (120): 1) Public perception of cell therapy – heightened expectations may 
influence the patient’s decision to participate in clinical studies with cell therapy and may 
also affect the randomization procedure, with a preference to be in the treatment arm of 
the study rather than in the control group; 2) conflicts of interest – commercial interests 
may place pressure on researchers to investigate cell therapies which are not yet ready for 
clinical testing; 3) risks vs. potential benefits  – given the invasive nature and uncertainties 
surrounding cell therapy, the potential risks may be difficult to define, thereby making the 
consent procedure all the more challenging; 4) choice of study outcome measure – there 
is a fine balance between choosing a surrogate endpoint which provides mechanistic 
insight, and a clinically relevant endpoint. 
 
4.2  Patient selection (co-morbidities and co-medications)  
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When considering efficacy of cell therapy, a better understanding of cell biology and the 
interaction between treatment and patient-specific cardiovascular risk factors, co-
morbidities (such as age, gender, diabetes, hypertension, dyslipidemia, smoking, 
depression and psychological stress), and routine medications is required. All major co-
morbidities and co-medications in patients with IHD are potential confounders of the 
efficacy of cell therapy, via affecting the quality of source cells as well as the response of 
host tissue to the transplanted cells (121-123). Autologous or allogeneic hematopoietic cell 
transplantation for hematologic diseases was the first type of cell therapy, the outcome of 
which was correlated with comorbidity indices (124). However, no data are available on 
comorbidity index or score systems to be used in clinical cell therapy trials in order to 
objectively and reproducibly assess the possible interference of pre-existing co-morbidities 
and co-medications with the outcome (121). In this regard, key points that should be 
considered are the following:  1) roughly equal stratification of patients into risk groups; 2) 
the inclusion of possible confounders in the analyses of outcomes; 3) evaluation of aging 
as a three-dimensional variable incorporating chronologic age (which is a poor predictor of 
cell therapy outcomes, probably due to a lack of data on organ dysfunctions (125)), co-
morbidities, physical function, nutritional and cognitive status; 4) developing useful 
prognostic biomarkers and co-morbidity index that could help understanding correlations 
between co-morbidities with either cell biology and host response before any cell therapy. 
 
In summary, careful attention must be given to a variety of factors (including age, 
gender, co-morbidities, concomitant medications, and any other cardiovascular risk 
factors) that may interfere with the regenerative potential of cell therapy in the 
setting of IHD and HF. The development of useful prognostic biomarkers and co-
morbidity indexes could help to objectively assess the weight of these factors in 
both preclinical and clinical trials. 
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4.3 Clinically relevant delivery routes, cell dose, and timing of delivery  
Catheter-based intracoronary cell infusion using a perfusion balloon catheter during stop 
flow conditions is the mostly used delivery route in clinical trials, with the following 
drawbacks: 1) the potential non-selective distribution pattern of the transferred cells, with 
exclusion of infarcted and border area in the case of an occluded coronary artery; 2) the 
need for the cells to transmigrate from the vessel lumen into the myocardium; 3) the 
possible occurrence of microembolisms with subsequent myocardial dysfunction.  
Intravenous administration is limited by entrapment of the donor cells in the capillaries of 
the lungs. Direct myocardial injection is the most precise and accurate type of delivery, 
however it requires anesthesia and prolonged recovery. Transcatheter transendocardial 
cell injection through the femoral artery and the aortic valve, is less invasive but requires 
expensive and time-consuming mapping systems that have a certain risk.  
In regard to cell dose (reviewed in (42)), it should be noted that in the vast majority of pre-
clinical and clinical studies, dosing has been non-systematic and empirically assessed, 
guided more by feasibility and accessibility rather than by intentional dosage optimization. 
This has contributed to the still open question of how many cells should be delivered in 
order to achieve clinical benefit. Mean numbers of cells infused into the coronary 
circulation of patients with IHD and HF range from 1.2 x 107 to 2.05±110 x 108 bone 
marrow cells and from 1 x 106 to 25 x 106 CSCs (reviewed in (42)). The optimal timing of 
donor cell delivery also remains debated. Although no consensus has been reached, 
between 4 (126) to 8 days (127) after AMI onset seemed to be the optimal time point for 
BMCs or circulating blood-derived progenitor cells delivery into an infarct-related coronary 
artery, based on the results and the inflammatory response in myocardial infarction. 
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4.4 How to assess the clinical benefit of cell therapy (including follow-up)  
In the vast majority of trials, the primary endpoint has been the evaluation of left ventricular 
size and global systolic function before and after treatment (reviewed (128)). Small (if any) 
improvements of LVEF have been observed in cell-treated patients by 2-dimensional 
echocardiography, MRI, left ventricular angiography, or radionuclide ventriculography 
performed at different time points and with different acquisition and analysis protocols 
(reviewed in (128)). Given the controversial outcomes of previous clinical trials, future 
studies should avoid imaging methodologies with poor reproducibility, should standardize 
timing of image acquisition and analysis protocols and more comprehensively evaluate the 
potential benefits deriving from cell therapy. Indeed, implementation and standardization of 
other techniques, such as 3D echocardiography (129), strain/strain rates (130, 131), tissue 
Doppler echocardiography (132, 133), and MRI might be extremely helpful to identify more 
sensitive markers of cardiac improvement. It is important to emphasize that, at the present 
time, MRI currently provides the most accurate, comprehensive, and reproducible 
measurements of cardiac chamber dimensions, volumes, function and infarct size 
compared to other techniques (134, 135), and therefore should be performed in cell-
treated patients enrolled in clinical trials whenever possible at baseline, after treatment and 
during follow-up. In addition to MRI, myocardial viability should be determined by 18F-FDG 
PET assessing glucose metabolism, alone or in association with dobutamine stress 
echocardiography, since all studies using 18F-FDG have shown an improvement in 
myocardial viability (136, 137), but this beneficial effect has not always been paralleled by 
an increase in contractile reserve (138). Finally, to precisely determine the effects of cell 
therapies on vasculogenesis, serial quantitative PET evaluations of global and regional 
myocardial perfusion might be extremely valuable (20, 137, 139). Independent of the 
specific technology, centralized evaluation by independent and blinded core labs should 
be standard. 
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In addition to the above endpoints, real, clinically relevant endpoints should also be used 
in future clinical trials, as e.g. indicated in the BAMI-trial that is focused on the effect of 
intracoronary reinfusion of BMCs on all cause mortality in AMI (NCT01569178). Although 
such trials need enough power and are costly, they are essential to demonstrate the net 
clinical benefit for patients. Additional standard tests that should be considered, include 
quality of life assessment, number of hospitalizations, 6 min walk tests, and death over 
several years’ follow-up. 
 
In summary, what clinical endpoint should be analyzed and by which method, how 
patient selection takes place and what the best clinically relevant delivery routes are 
for cell administration and which cell dose and timing of delivery should be used, 
are the most crucial aspects in clinical trials investigating the effects of cell therapy. 
Adequately powered large-scale clinical trials, taking into account all the possible 
safety and ethical issues and focusing on hard clinically-meaningful endpoints, are 
mandatory to determine whether the observed functional improvement reported in 
some studies can be extended to others and indeed translates into increased 
survival and reduced morbidity. 
 
5. Recommendations  
In Figure 1, we provide a flow-chart of experimental design starting from nonclinical 
studies and ending with the human clinical trials. To this translational pathway, we would 
like to make the following recommendations when assessing the clinical potential of 
conventional cell-based therapy, as well as novel strategies of cell enhancement for 
cardiac regeneration and repair in IHD and HF patients:  
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 Conventional cell-based therapy has been demonstrated to offer efficacy and safety in 
most experimental myocardial infarction models tested, including those in large 
animals, but in human clinical trials in IHD and HF patients only safety of cell therapies 
has been shown. Therefore, future pre-clinical studies using cell-based therapies 
should be designed to address specific hypotheses on modes of delivery and 
mechanisms of efficacy, rather than safety and efficacy endpoints only;   
 Based on the expected clinical trial outcome, a careful selection of cell source is 
essential: whereas first generation cells might be useful for stimulation of endogenous 
repair mechanisms or angiogenic effects, second generation cells truly aim at replacing 
damaged myocardium. A comparison of different cell types, or a combination of cell 
types in randomized clinical trials has not yet been performed but are being planned in 
future trials of chronic ischemic heart failure; 
 Assessing cell number and viability along with full cell characterization should be 
done in every clinical trial; 
 Poor cell retention remains a major issue. To further boost both cellular and paracrine 
effects, effective carrier materials or engineering approaches should be further 
developed;  
 To maximize successful translation of novel cell enhancement strategies, it is of 
primary importance to ensure that the efficacy of preclinical studies is validated in the 
presence of confounding factors, such as age and gender and common cardiovascular 
co-morbidities as well as their routine medications;  
 Use of hard clinically -meaningful endpoints is mandatory to determine whether 
functional improvement indeed translates into increased survival and reduced 
morbidity. 
 
6. Conclusions  
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The early promise of cell therapy has not yet been fulfilled. First-generation cells and their 
secretomes, that aim at myocardial salvage and stimulating the endogenous repair 
mechanisms of the heart through pro-angiogenic or prosurvival activity, should be carefully 
selected depending on the desired effect. Second-generation cells such as pluripotent 
stem cells are indisputably capable of forming beating contractile cardiomyocytes, but 
large surviving grafts of injected cells are rarely observed (140). Combining these cell 
types with biomaterials may enhance the outcome of present cardiac cell transplantation 
therapy, by truly replacing the damaged myocardium with muscular grafts. Other strategies 
to empower the donor cells, referred to as cell enhancement, may further stimulate 
paracrine effects, but new developments will be necessary to achieve cardiac regeneration 
e.g. by stimulating endogenous cardiac regeneration. Moreover, the selection of 
appropriate clinical endpoints, patient population, and delivery strategies are crucial 
aspects to understand the clinical effects. Furthermore, focusing on hard clinical endpoints 
in future cell-based trials is mandatory to determine whether any observed functional 
improvement translates into increased survival and reduced morbidity. 
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Figure legends 
Figure 1: Flow-chart of experimental design starting from preclinical studies and ending to the human clinical trials  
          
